NCT00037102View on ClinicalTrials.gov

Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis

PHASE4CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 31, 2001

Primary Completion Date

December 31, 2003

Study Completion Date

December 31, 2003

Conditions
Multiple Sclerosis
Interventions
DRUG

interferon beta 1a

DRUG

methotrexate

Sponsors

Collaborators (1)

Biogen
All Listed Sponsors
collaborator

Consultants in Neurology

INDUSTRY

collaborator

Biogen

INDUSTRY

lead

MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute

OTHER